Skip to main content

SCYNEXIS, Inc.

corporate_fare Company Profile

SCYNEXIS, Inc.

SCYX·NASDAQ·Life Sciences·CIK 0001178253

SCYNEXIS, Inc. is a pharmaceutical company focused on developing treatments for severe rare diseases, with a primary focus on difficult-to-treat and drug-resistant fungal infections. The company develops its proprietary antifungal platform called "fungerps," which are triterpenoids, a novel class of antifungal agents. These agents are glucan synthase inhibitors and have demonstrated activity against a broad range of human fungal pathogens, including Candida, Aspergillus, Pneumocystis, Coccidioides, Histoplasma, Blastomyces genera, and most common mucorales species, including multidrug-resistant strains. Ibrexafungerp, the first fungerp, was approved by the U.S. Food and Drug Administration (FDA) as BREXAFEMME (ibrexafungerp tablets) in 2021 for vulvovaginal candidiasis (VVC) and in 2022 for the reduction in the incidence of recurrent vulvovaginal candidiasis (rVVC). Ibrexafungerp was licensed to GSK in May 2023. A second-generation fungerp, SCY-247, is currently in clinical trials, and other compounds from the fungerp platform are in earlier development stages. The FDA has granted SCY-247 Qualified Infectious Disease Product status and Fast Track designations for its oral formulation. The company recently completed the single and multiple ascending dose portions of a Phase 1 study for oral SCY-247 in 88 healthy subjects. This study evaluated the safety, tolerability, and pharmacokinetics of SCY-247 at single ascending doses from 50mg to 900mg and multiple ascending doses from 50mg to 300mg, once daily for 7 days. A total of 66 participants received SCY-247 and 22 received placebo across these cohorts, and SCY-247 was well tolerated.

SCYNEXIS, Inc. (NASDAQ:SCYX) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 23 items for SCYX at importance 7 or higher on its 1–10 market-impact scale.

Recent high-impact activity:

  • SCYNEXIS Completes 'Transformative' Acquisition of Innovative ADPKD Drug PXL-770
  • Scynexis Reports $20.6M Revenue, Cuts Loss to $(0.17) EPS on Strategic GSK Deal
  • SCYNEXIS Secures $24.8M from GSK, Advances Lead Antifungal Program SCY-247, and Extends Nasdaq Compliance

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$20.6M
Net Income
-$8.61M
Diluted EPS
-$0.17
Op. Cash Flow
-$5.28M
Operating Income
-$16.07M
Cash & Equivalents
$21.26M
Debt / Equity
0.00×
Net Margin
-41.8%
Shares Outstanding
43.54M sh
Source: 10-K · filed 2026-03-04 · accession 0001178253-26-000007
$2.38
52-week range · as of 2026-11-05 $2.38 – $9.12
Market cap
$23.69M
Volume
156K (2.1× avg)
3-mo avg 75.3K
Live data · 2026-11-22 12:54 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed SCYX - Filings & News (Page 2)

SCYX
Mar 31, 2026, 6:40 AM EDT
Source: Dow Jones Newswires
Importance Score:
8
Price at Filing: $0.7897
Real-time Price: $2.38 info
Change: Reverse Stock Split info
Market Cap: $23.689M info
SCYX
Mar 04, 2026, 4:05 PM EST
Source: Wiseek News
Importance Score:
8
Price at Filing: $0.7752
Real-time Price: $2.38 info
Change: Reverse Stock Split info
Market Cap: $23.689M info
SCYX
Mar 04, 2026, 4:01 PM EST
Filing Type: 10-K
Importance Score:
9
Price at Filing: $0.775
Real-time Price: $2.38 info
Change: Reverse Stock Split info
Market Cap: $23.689M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets